Royal DSM, Amyris, Inc. Expand Alliance

Royal DSM and Amyris, Inc. have expanded their ongoing collaboration with the sale of Amyris Brasil Ltda to DSM, along with the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.

The sale of Amyris Brasil Ltda (which owns and operates the Brotas 1 production facility), intellectual property related to farnesene (a bio-based key intermediate for many applications), and an additional value share arrangement over a three-year period amounted to $96 million. 

With the acquisition of the Brotas 1 facility, DSM adds a biotechnology-based production site in Brazil to its global network. Amyris is accelerating the construction of their second facility dedicated to specialty products, but is maintaining the manufacturing process development and business support capability that Brotas 1 offers.

“We are very pleased with the continued expansion of our strategic alliance with DSM,” said John Melo, Amyris president and chief executive officer. “This manufacturing partnership and the sale of our Brotas 1 factory allows us to accelerate the development and manufacturing of specialty, high-performance ingredients. 

The strategic alliance between DSM and Amyris started in May 2017 with an equity investment by DSM in Amyris, and has since been expanded with several significant product development collaborations.